Dr. Kossen has 15 years of experience in pharmaceutical research, including drug discovery, drug development, and the characterization of disease biology. Dr. Kossen was previously Vice President of Disease Biology at InterMune, where he focused on the detailed profiling of antifibrotic drugs and biomarkers of fibrotic disease. He also facilitated external collaborations to further elucidate the pathobiology of idiopathic pulmonary fibrosis. Following the acquisition of InterMune by Roche in 2014, Dr. Kossen co-founded Blade Therapeutics and served as Senior Vice President of Biology. His efforts at Blade helped advance the therapeutic discovery pipeline and enable a $45 million capital raise. Dr. Kossen received his B.S. in Chemistry and Cell & Molecular Biology from the University of Michigan and his Ph.D. in Biochemistry from the University of Colorado.